Avacta (LON: AVCT) shares have barely budged at open - half a percent - on the back of news of success in their Korean joint adventure. The puzzle is why this is producing such a small price change. For the news release is good enough. They've reached the second stage, that second stage payment (which is in the form of ownership of the JV) is triggered, this is good, right? “pleased to announce that a second milestone equity payment has been triggered resulting in an increase in Avacta's shareholding in AffyXell Therapeutics ("AffyXell"), a joint venture to develop next-generation cell therapies between Avacta and Daewoong Pharmaceutical ("Daewoong") in South Korea.”
It's not just that the second stage equity allocation has been triggered. That it has been shows also that the base technology being implemented is working according to plan. Which is also good, right? There's also that fact that this is the most read news release this morning on the entire London stock market. Now, true, at our pixel time the market's only been fully open for 20 minutes and things can change. But we really would expect more than merely half a percent here. So, why not?

Avacta share price from London Stock Exchange
Our read on this is as with Genedrive. Or more recently with Rhythm Biosciences on the ASX. Stock markets have memories - because the people who make up stock markets have memories. And there was a handful of companies - Avacta and Genedrive among them - who in the depths of the covid pandemic worked on creating lateral flow tests. That's great, just what we want to happen of course, the pharma industry stepping up. But there was a time when (Genedrive first, from memory, others following, Rhythm has done this much more recently with a different product) people were announcing CE Marks. As if they were some authorisation, approval, to sell onto the EU market. Share prices doubled, tripled, on said news. But a CE Mark is just a piece of paperwork. Fill it out, pay the fee, gain a CE Mark. Sure, you've got to have one to sell in the EU but it's not an approval, nothing like FDA testing. Even though some investors treated the CE Mark like it was an FDA equivalent approval.
As we say, markets have memories. Those CE Mark gains all faded away in time. So, among those companies there's a certain scepticism about announcements of this or that. Actual cashflow, profits even, would be different. But that old once bitten twice shy idea might come into play here. Well, that's our opinion anyway.



